Opinion

Video

ADCs Targeting GI Cancers

Author(s):

Vijayakrishna Gadi, MD, University of Illinois College of MedicineSusana Campos, MD, MPH

Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.

Video content above is prompted by the following:

  • Please review the data for T-DM1 for:
    • HER2+ advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocaricoma: GATSBY; Shah-Gastric Cancer_2019: Biomarker analysis of GATSBY
    • T-DM1 + Pertuzumab for HER2-amplified colorectal cancer: HERACLES-B trial
  • Please review the data for T-DXd for:
    • HER2+ gastric or GEJ: DESTINY-Gastric01; Shitara_Nature Med_2024: Biomarker Analysis of DESTINY-Gastric01 and DESTINY-Gastric02
    • Unresectable or metastatic HER2+ CRC: DESTINY-CRC01 1. DESTINY-CRC02 – Raghav_ASCO 2023
    • HER2+ and HER2-low GC: DESTINY-Gastric03 Janjigian ASCO 2024
    • Retrospective Cohort Study EN-DEAVOR: Nakanishi ASCO 2024
  • What is the potential for HER2-targeting ADCs in other GI cancers?
    • Biliary Tract Cancers, Pancreatic
      • PanTumor02: Meric-Bernstam_J Clin Oncol_2024; a. BTC and PC Cohort Outcomes: Oh ASCO 2024 #4090
      • HERB trial (BTC): Ohba_ASCO2022
  • Where do HER2-directed ADCs fit into the treatment armamentarium for GI cancers?
  • Is there an unmet need ADCs could help fill?

Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
1 KOL is featured in this series.
3 KOLs are featured in this series.
Related Content